Study details
Enrolling now
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
Ebrahim S Delpassand
NCT IDNCT06972628ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
30
Study length
about 3.9 years
Ages
18+
Sex
Male only
Locations
1 site in TX
About this study
This trial is testing a treatment called Lutetium-177-PSMA-617 (PLUVICTO) in men with advanced prostate cancer that has spread to the bones. The goal is to see if PLUVICTO is safe and well-tolerated for these patients.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Administering Lutetium-177-PSMA-617 (PLUVICTO)
PhasePhase 2
Primary goalOverall Survival
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low11%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Overall Survival, Radiographic progression-free survival
Body systems
Oncology